Resmed (RMD) Net Equity Issued and Repurchased (2009 - 2026)

Resmed (RMD) has 18 years of Net Equity Issued and Repurchased data on file, last reported at $7.4 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 17.69% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.3 million (up 4.68% YoY) and the FY2025 annual result came in at $74.4 million, up 40.2% from the prior year.
• Net Equity Issued and Repurchased retreated to $7.4 million in Q1 2026, from $29.6 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $30.2 million in Q2 2025 to a low of $983000.0 in Q1 2023.
• A 5-year average of $14.5 million and a median of $9.0 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased surged 1840.69% — and 2023, when it plunged 65.07%.
• Tracing RMD's Net Equity Issued and Repurchased over 5 years: stood at $22.1 million in 2022, then declined by 11.48% to $19.5 million in 2023, then surged by 37.66% to $26.9 million in 2024, then grew by 9.97% to $29.6 million in 2025, then tumbled by 74.87% to $7.4 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $7.4 million (Q1 2026), $29.6 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.